Compare BridgeBio Pharma Inc (BBIO) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Atlassian Corporation PLC — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Atlassian Corporation PLC trades at $92 (market cap $22.62B). The key difference: Atlassian Corporation PLC is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| BBIO | TEAM | |
|---|---|---|
Market Cap | $16.46B | $22.62B |
Sector | Health | Technology |
52-Week High | $90.17 | $203.00 |
52-Week Low | $44.81 | $57.15 |
Enterprise Value | $18.02B | $22.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Atlassian (TEAM) trades at $96.11, up 8.16% today, with strong technical momentum and bullish analyst sentiment. The stock shows accelerating revenue growth (32% YoY in Q3 FY26 per Zacks Investment Research, 2026-06-24) and improving margins, though it remains unprofitable. Recent earnings beats and cloud business expansion support positive outlook, while high valuation multiples and competitive pressures present risks.
Outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent net losses and elevated valuation. Wall Street consensus price target of $115.69 suggests 20% upside, though execution on profitability is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
